Khalid M. Kamal
Tanzania
Research Article
Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis
Author(s): Rituparna Bhattacharya and Khalid M. KamalRituparna Bhattacharya and Khalid M. Kamal
Objective: Tofacitinib is a novel oral biologic that has been approved for treating adults with Rheumatoid arthritis (RA) having inadequate response to or are intolerant of methotrexate (MTX). The objective of this study was to conduct a budget impact model (BIM) analysis for estimating direct annual drug costs for individuals with RA before and after the introduction tofacitinib as a formulary option. Research Design and Methods: The BIM was developed using a US healthcare payer?s perspective with a one-year time frame. The tumor necrosis factor inhibitors (anti-TNFs) adalimumab, etanercept, infliximab, golimumab and certolizumab were considered as comparators. The BIM tested two base-case scenarios: ?Base-case scenario 1: Incident anti-TNF users?; ?Base-case scenario 2: Prevalent anti-TNF users?. Both the scenarios were evaluated under the following two conditions: (1) assuming mono.. View More»
